Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
Leslie Citrome Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA Abstract: Cariprazine is an oral antipsychotic approved in the US and EU for the treatment of schizophrenia. Cariprazine differs from other antipsychotics in that it is a dopamine D3- and D...
Enregistré dans:
Auteur principal: | Citrome L |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2018
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/6776b85ca77941779d2f21b58ef17f49 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
par: Barabássy Á, et autres
Publié: (2021) -
Cariprazine: Patients with Treatment-Resistant Schizophrenia
par: Aubel T
Publié: (2021) -
Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]
par: Barabássy Á, et autres
Publié: (2021) -
Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms
par: Octavian Vasiliu
Publié: (2021) -
Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience
par: Montes JM, et autres
Publié: (2021)